Richard R. Sharp

Richard R. Sharp

Auto-generated profile, based on publicly available information

Richard R. Sharp

Department of Bioethics, Cleveland Clinic, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in JAMA
Verified
Journal Article
Closed access
PDF file
AGAaron J. Goldenberg
Aaron J. Goldenberg
RSRichard R. Sharp
Richard R. Sharp
Advances in next-generation sequencing technologies have the potential to spur better integration of genetic testing into patient care. Appropriate utilization

8 March 2012 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
JMJennifer B. McCormick
Jennifer B. McCormick
RHRachel R Hammer
Rachel R Hammer
RFRuth Farrell
Ruth Farrell
GGGail Geller
Gail Geller
KJKatherine M James
Katherine M James
RSRichard R Sharp
Richard R Sharp
Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) are chronic conditions affecting millions of individuals in the United States. The symptoms are well-documented and can be debilitating. How these chronic gastrointestinal (GI) conditions impact the daily lives of those afflicted is not well documented, especially from a patient's perspective.


14 April 2013 in Human Reproduction
Verified
Journal Article
Open access
PDF file
DCD. Cho
D. Cho
MMM. L. McGowan
M. L. McGowan
JMJ. Metcalfe
J. Metcalfe
RSR. R. Sharp
R. R. Sharp
How do genetics professionals assess the potential benefits and challenges of expanded carrier screening (ECS) in reproductive healthcare? Genetics professionals believe that current ECS products have major limitations and are not ready for routine use in reproductive healthcare. Non-targeted approaches to carrier screening have been met with uneven enthusiasm from relevant professional organizations. With declining genotyping costs, it is reasonable to expect that the number of genetic conditions evaluated by carrier-screening products will continue to increase. Reproductive healthcare providers will play a critical role in the adoption of ECS and need to be prepared for the potential challenges that lie ahead. Focus groups were convened at six academic medical centers in the USA in March 2011 to examine genetics professionals' views on ECS. Forty genetic professionals participated in six focus groups for this study. A clinical case report was presented to each focus group to examine participants' opinions about the use of highly multiplexed forms of carrier screening in reproductive healthcare. Focus group transcripts were analyzed for major themes and thematic density across sites using qualitative data analysis software (ATLAS.ti v5.8). Participants believed that current ECS products have major limitations pertaining to the analysis of select alleles and genetic mutations. Participants highlighted multiple interpretive and counseling challenges that reproductive healthcare providers may face in communicating ECS results to patients. Participants stressed the importance of communicating these and other limitations to patients before recommending ECS. Participants recommended collaboration with genetic counselors and medical geneticists in providing ECS. To the extent that ECS products have not been widely used to date, participants may have had limited familiarity and direct clinical experience with these products. Given that this study was conducted with genetic professionals from academic medical centers in the USA, participant perspectives may not be representative of professional practices and norms in other healthcare settings. In considering the use of ECS products in their practices, reproductive healthcare providers may find it helpful to consider the perspectives of genetics professionals. These specialists have considerable experience with diverse forms of genetic testing and can provide valuable insights regarding new genomic risk assessment tools such as ECS. This research was supported by the National Human Genome Research Institute (R01 HG004500 and P50 HG003390). None of the authors have any conflicts of interest to declare.

20 June 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
BWBenjamin S. Wilfond
Benjamin S. Wilfond
DMDavid Magnus
David Magnus
AAArmand H. Antommaria
Armand H. Antommaria
PAPaul Appelbaum
Paul Appelbaum
JAJudy Aschner
Judy Aschner
SYStuart Youngner
Stuart Youngner
We are a group of scholars and leaders in bioethics and pediatrics with extensive experience in ethical and regulatory issues in pediatrics and human subjects research. We urge the Office for Human Research Protections (OHRP) to withdraw its notification to the institutions involved in the Surfactant, Positive Pressure, and Oxygenation Randomized Trial (SUPPORT) that they failed to meet regulatory informed-consent requirements, in particular regarding reasonably foreseeable risks of enrollment in the study. We believe that this conclusion was a substantive error and will have adverse implications for future research.

1 February 2012 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
MMMaryBeth Mercer
MaryBeth Mercer
MBMargaret A. Ba Brinich
Margaret A. Ba Brinich
GGGail ScD Geller
Gail ScD Geller
KHKrista Ba Harrison
Krista Ba Harrison
JHJanelle Ma Highland
Janelle Ma Highland
RSRichard R. Sharp
Richard R. Sharp
Background Patients with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) have access to a growing number of probiotic products marketed to improve digestive health. It is unclear how patients make decisions about probiotics and what role they expect their gastroenterologists to play as they consider using probiotics. Understanding patients’ knowledge, attitudes and expectations of probiotics may help gastroenterologists engage patients in collaborative discussions about probiotics. Study Focus groups were conducted with patients with IBD and IBS at the Cleveland Clinic, Mayo Clinic, and Johns Hopkins University. Inductive analytic methods were used to identify common themes and draw interpretations from focus group narratives. Results One hundred thirty-six patients participated in 22 focus groups between March and August 2009. Patients viewed probiotics as an appealing alternative to pharmaceutical drugs and understood probiotics as a more “natural,” low-risk therapeutic option. Many patients were hesitant to use them without consulting their gastroenterologists. Patients would weigh the risks and benefits of probiotics, their disease severity and satisfaction with current treatments when considering probiotic use. Conclusions Patients are interested in probiotics but have many unanswered questions about their use. Our findings suggest that patients with IBD and IBS will look to gastroenterologists and other clinicians as trustworthy advisors regarding the utility of probiotics as an alternative or supplement to pharmaceutical drugs. Gastroenterologists and other clinicians who care for patients with these diseases should be prepared to discuss the potential benefits and risks of probiotics and assist patients in making informed decisions about their use.